Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.94% |
| 2 | Consumer Discretionary | 14.99% |
| 3 | Communication Services | 11.27% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
TransDigm Group
TDG
$73.2B
| $111M | 0.11% |
687,956
-573,786
| -45% | -$85.5M |
|
177
Oneok
OKE
$55.9B
| $109M | 0.11% |
2,001,998
+133,724
| +7% | +$6.7M |
|
178
Range Resources
RRC
$8.94B
| $108M | 0.11% |
1,285,414
-28,646
| -2% | -$2.23M |
|
179
East-West Bancorp
EWBC
$18B
| $108M | 0.11% |
3,091,580
-39,096
| -1% | -$1.33M |
|
|
DATA
180
DELISTED
Tableau Software, Inc.
DATA
| $108M | 0.11% |
1,564,361
+1,424,697
| +1,020% | +$93.3M |
|
181
NRG Energy
NRG
$26.9B
| $107M | 0.11% |
3,742,943
-76,286
| -2% | -$2.13M |
|
182
Albemarle
ALB
$13.3B
| $107M | 0.11% |
1,688,937
-28,916
| -2% | -$1.92M |
|
183
Energy Transfer Partners
ET
$69.5B
| $107M | 0.11% |
5,236,520
+794,560
| +18% | +$14.3M |
|
184
Cogent Communications
CCOI
$649M
| $107M | 0.1% |
2,639,615
-164,769
| -6% | -$6M |
|
185
Zoetis
ZTS
$32.5B
| $106M | 0.1% |
3,242,563
+2,111,935
| +187% | +$67.4M |
|
|
SPN
186
DELISTED
Superior Energy Services, Inc.
SPN
| $105M | 0.1% |
396,429
+9,891
| +3% | +$2.59M |
|
187
NextEra Energy
NEE
$186B
| $105M | 0.1% |
4,905,608
-93,468
| -2% | -$1.97M |
|
188
Standard BioTools
LAB
$311M
| $103M | 0.1% |
2,690,748
-679,712
| -20% | -$20M |
|
189
Sanofi
SNY
$109B
| $102M | 0.1% |
1,905,142
+355,785
| +23% | +$18.4M |
|
|
HES
190
DELISTED
Hess
HES
| $102M | 0.1% |
1,227,152
+728,894
| +146% | +$59.2M |
|
191
Lumen
LUMN
$6.38B
| $102M | 0.1% |
+3,188,024
| New | +$102M |
|
192
Sempra
SRE
$59.2B
| $101M | 0.1% |
2,258,556
+162
| +0% | +$7.19K |
|
|
MNDT
193
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $101M | 0.1% |
+2,322,214
| New | +$90.8M |
|
|
CAVM
194
DELISTED
Cavium, Inc.
CAVM
| $100M | 0.1% |
2,908,011
+429,792
| +17% | +$16.1M |
|
195
Capital One
COF
$130B
| $99.8M | 0.1% |
1,303,086
-15,281
| -1% | -$1.09M |
|
196
Bread Financial
BFH
$4.36B
| $97.5M | 0.1% |
464,569
-346,371
| -43% | -$66.1M |
|
197
Celldex Therapeutics
CLDX
$2.79B
| $96.4M | 0.09% |
265,454
-19,404
| -7% | -$7.48M |
|
|
XEC
198
DELISTED
CIMAREX ENERGY CO
XEC
| $96.1M | 0.09% |
915,914
-104,924
| -10% | -$10.6M |
|
199
GameStop
GME
$9.94B
| $95.4M | 0.09% |
7,747,444
+161,620
| +2% | +$2.07M |
|
200
OGE Energy
OGE
$10.2B
| $94M | 0.09% |
2,773,570
| – | – |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.